Skip to main content
. 2021 May 26;11(8):2150–2171. doi: 10.1016/j.apsb.2021.05.020

Figure 3.

Figure 3

Viral vector-mediated in vivo therapeutic genome editing. (A) Schematic representation of dual AAV8 strategy for site-specific gene insertion in hepatocytes treating Hemophilia B52. Copyright Elsevier 2020. Under the permission of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CC BY-NC-ND 4.0) (https://creativecommons.org/licenses/by-nc-nd/4.0/). (B) AAV9 for systemic delivery of CRISPR-Cas9 for deletion of SIV proviral DNA in ART treated rhesus macaques158. Copyright Springer Nature 2020. Under the permission of the Creative Commons Attribution 4.0 international license (CC BY 4.0) international license (CC BY 4.0). (https://creativecommons.org/licenses/by/4.0/) (C) AAV1 for systemic delivery of CRISPR-Cas9 for disruption of mutant HTT in medium sized spiny neurons to treat Huntington’s disease144. Copyright Elsevier 2019. Under the permission of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CC BY-NC-ND 4.0) (https://creativecommons.org/licenses/by-nc-nd/4.0/). (D) Systemic lentiviral delivery of CRISPR-Cas9 for KRAS disruption to suppress colorectal adenocarcinoma growth72. Copyright Cold Spring Harbor Laboratory Press 2018. Under the permission of the Creative Commons Attribution-Non Commercial License 4.0 (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/).